WO2016204026A1

WO2016204026A1 - Nostril indwelling device

Info

Publication number: WO2016204026A1
Application number: PCT/JP2016/066916
Authority: WO
Inventors: 阪根　信一; 幹太倉内; 貴史本田; 坂尻　浩一
Original assignee: ｓｅｖｅｎｄｒｅａｍｅｒｓｌａｂｏｒａｔｏｒｉｅｓ株式会社
Priority date: 2015-06-15
Filing date: 2016-06-07
Publication date: 2016-12-22
Also published as: JPWO2016204026A1

Abstract

The present invention provides a nostril indwelling device 1A which is provided with an insert 10A that has both a proximal end 103 and a distal end 104 in the length direction, and which can allow the insert 10A to dwell in nasal cavity. In the device, the insert 10A is provided with a drug-retaining section 101 which can retain a drug, and at least a part of the drug-retaining section 101 is so configured as to be exposed at a contact surface 102 lying between the proximal end 103 and the distal end 104 of the insert 10A and is also so configured that the contact surface 102 and the mucosa of nasal cavity can contact with each other during the dwelling of the device.

Description

Nasal indwelling device

The present invention relates to a nasal cavity indwelling device.

Conventionally, as a device for administering a drug or the like parenterally, a patch such as an adhesive patch holding the drug in a contact portion with skin or mucous membrane has been known (for example, see Patent Document 1).

JP 2009-051840 A

However, with this patch, when the patch is used on the mucous membrane, it is difficult to maintain the adhesive strength of the patch due to mucus secreted from the mucous membrane, and it easily falls off in a short time. In addition, it is difficult to use a patch or to recover the mucous membrane that is not exposed on the surface of the body such as the nasal cavity.

Therefore, an object of the present invention is to provide a nasal indwelling device capable of bringing drugs into contact with the mucous membrane for a certain period of time.

A nasal indwelling device comprising an insert having a longitudinally proximal end and a distal end, for placing the insert in the nasal cavity,
The insert includes a drug holding unit capable of holding drugs,
At least a part of the medicine holding part is exposed on the surface between the proximal end and the distal end of the insert, and is configured so that the surface and the mucous membrane of the nasal cavity come into contact with each other at the time of placement. Yes.

According to the above configuration, the insert is inserted from the nostril into the nasal cavity and placed in the nasal cavity. The contact surface of the insert placed in the nasal cavity is in contact with the mucous membrane of the nasal cavity with the drug holding part holding the drug exposed. Therefore, the drugs can be brought into contact with the mucous membrane for a desired time.

In the nasal cavity placement device, the nasal cavity placement device further comprises a nasal cavity mounting body for mounting the insert body on the nasal cavity,
The nasal cavity mounting body is preferably connected to the proximal end of the insert.

According to the above configuration, when the nasal cavity placement device is inserted into the nasal cavity from the distal end of the insert body, the nasal cavity mount body is connected to the proximal end of the insert body. Located in. Therefore, the nasal cavity mounting body inside or outside the nostril can be operated with fingers or the like, and the nasal cavity mounting body can be mounted in the state where the insertion body is placed in the nasal cavity on the nostril side. Similarly, the nasal cavity wearing body can be operated with fingers or the like, and the insertion body can be pulled out from the nasal cavity.

In the nasal cavity placement device, the insert is preferably a tube having a circular cross section.

According to the above configuration, since the insert is a tube having an annular cross section, when the insert is placed in the nasal cavity, fluid such as air and mucus can flow into and out of the insert. The fluid flowing in from the nostril side can flow into and out of the pharynx side, and the fluid flowing in from the pharyngeal side can flow into and out of the nostril side through the tube of the insert. Therefore, physiological phenomena such as nasal breathing are not easily inhibited by the nasal cavity placement device. In addition, since the surface area of the insert is increased, it is possible to hold the drug on the back surface as well as on the back surface of the tube in the drug holding section.

In the nasal cavity placement device, it is preferable that an opening is defined between the nasal cavity wearing body and the proximal end of the insertion body.

According to the above configuration, when the insert is placed in the nasal cavity, the mucous membrane of the nasal cavity placement device is exposed from the nostril to the opening toward the nasal cavity wearing body. Inhalation from the nostril side toward the pharynx side comes into contact with the exposed mucous membrane and then flows into the insert through the opening. Therefore, the nasal cavity indwelling device hardly inhibits the physiological action of humidification and warming of inspiration by the mucous membrane.

In the nasal cavity placement device, the nasal cavity mounting body includes a support portion that extends toward the insertion body and is connected to a proximal end of the insertion body,
It is preferable that the support portion has higher rigidity than the insert.

According to the above configuration, when the insertion body is inserted from the nostril toward the nasal cavity, the insertion body can be inserted while the rigid support portion supports the insertion body. Therefore, the insert can be easily inserted into the nasal cavity.

In the nasal cavity placement device, the insert is preferably a tube having a U-shaped cross section.

According to the above configuration, when the insert is placed in the nasal cavity, the insert is formed with a portion that opens in the longitudinal direction. Inhalation from the nostril side toward the pharynx side can contact the mucous membrane at the opening. Therefore, the nasal cavity indwelling device hardly inhibits the physiological action of humidification and warming of inspiration by the mucous membrane. In addition, since the back of the tube is exposed at the part that opens in the longitudinal direction, the medicines can be easily held on the back of the tube by spraying or other methods even after it is molded into the tube of the insert. Can be made.

In the nasal cavity indwelling device, the insert includes a thin plate-like part provided with the medicine holding part,
The thin plate-like portion preferably has a shorter length than the nasal cavity wearing body.

According to the above configuration, when the insert is placed in the nasal cavity, the thin plate-like part having a large length in the short direction extends in the nasal cavity. Therefore, it becomes easy to bring the medicine holding part provided in the thin plate-like part into contact with the mucous membrane at a predetermined position of the nasal cavity.

In the nasal cavity indwelling device, the thin plate portion is preferably elastically deformable.

According to the above configuration, when the insert is inserted from the nostril toward the nasal cavity, the thin plate-like portion of the insert is elastically deformed according to the shape of the nasal cavity. Therefore, the insert can be easily inserted into the nasal cavity.

In the nasal cavity indwelling device, it is preferable that the thin plate-like portion is configured by connecting a plurality of sheet-like members to each other.

According to the above configuration, when the insert is placed in the nasal cavity, each of the plurality of sheet-like members can contact the mucous membrane at a predetermined position. Therefore, the medicine holding part provided in the thin plate-like part can be brought into contact with the mucous membrane at a plurality of locations. In addition, the surface area of the inserted body is larger than that of a thin plate-shaped portion formed of a single sheet-like member, and the area in contact with the mucous membrane can be increased. Furthermore, since a gap is formed between the sheet-like members, physiological phenomena such as nasal breathing are not easily inhibited.

In the nasal cavity indwelling device, it is preferable that a cross section of the thin plate-like portion has a shape that becomes thinner toward a surface side where the medicine holding portion is exposed.

According to the above configuration, when the insert is inserted from the nostril toward the nasal cavity, the cross section of the thin plate-like part is similar to the shape of the nostril and nasal cavity, and the deformation required for the insert is small. Therefore, the insert can be easily inserted into the nasal cavity. Moreover, since there is a relatively thick part in the shape of the thin plate-like part, a large amount of drugs can be held in that part.

In the nasal cavity placement device, it is preferable that the length of the thin plate-like portion in the short direction decreases along the distal end.

According to the above configuration, when the insertion body is started to be inserted from the nostril toward the nasal cavity, the thin plate-like portion has a short length in the short direction on the distal end side of the insertion body where the insertion is started. Therefore, the insertion of the insert can be easily started. Further, on the proximal end side of the insert that comes into contact with the mucous membrane, since the thin plate-like portion has a large length in the short direction, the medicine holding portion provided in the thin plate-like portion is attached to the mucosa in a predetermined position. It becomes easy to make it contact.

In the nasal cavity indwelling device, the nasal cavity mounting body includes a support portion that is connected to a proximal end of the insert and is intubated into the insert.
It is preferable that the support portion has higher rigidity than the insert.

In the nasal cavity placement device, it is preferable that the nasal cavity wearing body includes a pair of sandwiching portions facing each other and an elastically deformable coupling portion that couples the pair of sandwiching portions.

According to the above configuration, when the insert is placed in the nasal cavity, the pair of holding parts of the nasal cavity wearing body is placed with the nose column or nose wings sandwiched between fingers or the like. A pair of arranged clamping parts clamp a nasal column or a nasal wing with the elastic force of the connection part which connects them. Therefore, the insertion body can be stably mounted in a state of being placed in the nasal cavity via the nasal cavity mounting body to be connected.

In the nasal cavity indwelling device, the nasal cavity wearing body includes a locking portion having a circular outer periphery,
It is preferable that the locking portion is locked to the nasal vestibule when the insert is placed.

According to the above configuration, when the insert is placed in the nasal cavity, the locking part of the nasal cavity mounting body is locked in the nasal vestibule. Therefore, it is possible to suppress a sense of incongruity with the nostril without applying a load to the nose column or wing. Further, since the entire nasal cavity wearing body can be placed in the nasal cavity to such an extent that it can be extracted from the nostril, in that case, the nasal cavity placement device is not exposed outside the nasal cavity.

In the nasal cavity placement device, the nasal cavity mounting body is preferably a spring-like member having a C-shaped cross section.

According to the above configuration, when the insertion body is inserted from the proximal end toward the nasal cavity from the nostril, the nasal cavity mounting body, which is a C-shaped spring member, is closed by applying an external force to the spring member with fingers or the like. To insert into the nasal cavity. After the insertion, the external force applied to the spring member is released and opened, and the open spring member is locked in the nasal vestibule or nostril. Therefore, it can be locked at any position in the nasal vestibule and nostril.

In the nasal cavity placement device, the mucous membrane preferably includes at least a kieselbach region.

According to the above configuration, when the insert is placed in the nasal cavity, the contact surface of the insert comes into contact with the kieselbach region. In the Kieselbach region, veins are concentrated under the mucous membrane of the region, so that the absorbability of drugs is high. Therefore, the absorbability of the held medicines can be improved.

In the nasal cavity indwelling device, it is preferable that the medicine holding part has a porous structure.

According to the above configuration, when the drug is held in the insert, the drug holding part having a porous structure absorbs and holds the drug in the porous part. Therefore, a larger amount of drugs can be retained.

In the nasal cavity indwelling device, the medicine holding unit preferably has a matrix structure.

According to the above configuration, when the insert is placed in the nasal cavity, the drug is absorbed through the matrix structure from the surface where the drug holding portion is exposed to the mucosa where the surface is in contact. The matrix structure has an effect of relaxing the absorption rate of drugs. Therefore, the time for which the drugs are absorbed by the mucous membrane can be extended. The matrix structure is formed as a crosslinked structure by polymerizing monomers and / or polymers. Therefore, by setting the reaction conditions of the polymerization reaction (for example, reaction temperature, monomer and polymer composition, concentration) to a predetermined condition, good reproducibility of the cross-linked structure is obtained, and the absorption rate between the nasal indwelling devices is increased. Variations can be suppressed.

The nasal cavity indwelling device according to the present invention is capable of bringing drugs into contact with the mucous membrane for a certain period of time.

(A) It is a front view which shows typically an example of the nasal cavity indwelling device which concerns on Embodiment 1 of this invention. (B) It is a left view. It is a figure which shows typically an example of the state by which the C-shaped spring member which concerns on Embodiment 1 of this invention was used for the nose. (A) It is the front view which looked through the nose from the nasal septum side which shows typically an example of the state by which the insert which concerns on Embodiment 1 of this invention was detained in the nasal cavity. (B) It is the figure which saw through the nose from the nasal column side. (C) It is the rear view which saw through the nose from the left cheek side. (A) It is a front view which shows typically the modification of the insertion body which concerns on Embodiment 1 of this invention. (B) It is a left view. (A) It is the front view which looked through the nose from the nasal septum side typically showing the modification of the state where the insert concerning Embodiment 1 of the present invention was detained in the nasal cavity. (B) It is the figure which saw through the nose from the nasal column side. (C) It is the rear view which saw through the nose from the left cheek side. (A) It is a front view which shows typically an example of the nasal cavity indwelling device which concerns on Embodiment 2 of this invention. (B) It is a left view. (A) It is the front view which looked through the nose from the nasal septum side which shows typically an example of the state by which the insert based on Embodiment 2 of this invention was detained in the nasal cavity. (B) It is the figure which saw through the nose from the nasal column side. (C) It is the rear view which saw through the nose from the left cheek side. (A) It is a front view which shows typically the modification 1 of the insertion body which concerns on Embodiment 2 of this invention. (B) It is a left view. (A) It is a front view which shows typically the modification 2 of the insertion body which concerns on Embodiment 2 of this invention. (B) It is a left view. It is a front view which shows typically an example of the state by which the latching | locking part of the nasal cavity mounting body which concerns on embodiment of this invention was latched by the nasal vestibule. It is a front view which shows typically the modification of the nasal cavity mounting body which concerns on embodiment of this invention. It is a front view which shows typically the modification of the nasal cavity mounting body which concerns on embodiment of this invention. It is a perspective view which shows typically an example of a nasal cavity mounting body provided with a pair of clamping part and connection part which concern on embodiment of this invention.

Hereinafter, a nasal cavity placement device according to an embodiment of the present invention will be described in detail with reference to the accompanying drawings. However, the present invention is not limited to the embodiments.

[Embodiment 1]
First, the first embodiment will be described. In this embodiment, the insert is a tube.

(overall structure)
First, the configuration of the nasal cavity placement device 1A will be described. FIG. 1A is a front view schematically showing an example of the nasal cavity indwelling device according to the first embodiment. FIG. 1B is a left side view. As shown in FIG. 1 (A), the nasal cavity placement device 1A includes an insertion body 10A and a nasal cavity mounting body 20A along the longitudinal direction (the X direction in FIG. 1 (A)). Inserted and placed in nasal cavity. The term “indwelling” refers to the retention of drugs, which will be described later, to the extent necessary to absorb the mucous membrane for a predetermined amount and for a predetermined time. The time is appropriately set according to the drug, and is, for example, 5.0 minutes to 30 days, and preferably, for example, 5.0 minutes to 10 minutes when the drug is insulin. For example, when the drug is nicotine, the time is preferably 3.0 hours to 6.0 hours.

(Configuration-Insert)
The insert 10A is a cross-sectional annular tube comprising a drug retaining portion 101, a contact surface 102, a proximal end 103, a distal end 104, a proximal end opening 105, and a distal end opening 106. is there. In the following description, the length in the longitudinal direction (X direction in FIG. 1 (A)) of the nasal cavity placement device 1A is the length, the dimension in the short direction (Z direction in FIGS. 1 (A) and (B)) is the width, The dimension in the direction perpendicular to the longitudinal direction and the single-handed direction (the Y direction in FIGS. 1A and 1B) is defined as the width.

The length of the insert 10A is preferably, for example, 10 mm to 80 mm, and more preferably 30 mm to 80 mm, and even more preferably 50 mm to 80 mm when increasing the amount of drugs to be held. However, when the length of the support 202 is extended to, for example, 20 mm to 40 mm, the insertion body 10A may be less than this in accordance with the amount of drugs to be held. The thickness and width of the insert 10A are preferably 8.0 mm to 40 mm. However, if there is no limitation on the amount of the drug to be retained and the contact area with the nasal mucosa, the amount may be less than this in order to reduce the uncomfortable feeling when placed in the nasal cavity. The thickness of the tube (the difference between the radius of the outer diameter of the tube and the radius of the inner diameter) is preferably, for example, 0.1 mm to 5.0 mm.

The material of the insertion body 10A is not particularly limited as long as it can be placed in the nasal cavity, and examples thereof include resins such as silicone and thermoplastic resin. High-pressure steam sterilization, ethylene oxide gas, γ-ray sterilization, etc. To avoid deterioration of the material, silicone is preferred.

The drug holding unit 101 is configured to hold drugs. For example, the medicine holding unit 101 may be configured to hold the medicine by encapsulating the medicine in the layer of the insert 10A. More specifically, the medicine holding unit 101 may have a porous structure or a matrix structure.

The method having a porous structure is not particularly limited, and examples thereof include a method of forming the insert 10A itself as a porous body, and a method of bonding the porous body to the outer surface of the tube to form an insert. . The porous structure is not particularly limited as long as it has a porous part capable of holding drugs, but the average pore size is preferably 3.0 nm to 300 μm. In order to hold hydrophobic molecules, 6.0 nm More preferably, it is ˜10.0 nm. Further, in the case of a configuration having a porous structure, the flexibility of the insert 10A is increased and insertion is facilitated.

Note that the medicine holding unit 101 may have a matrix structure to hold a medicine. In the case of the matrix structure, the absorption rate of the drugs in the nasal mucosa is reduced, and the drugs are continuously released for a longer time. A method having a matrix structure is not particularly limited. For example, a method of forming the insert itself as a matrix structure by a sol-gel method, and a method of coating the matrix structure by applying a polymer to the surface of the insert and causing a crosslinking reaction, etc. The method of doing is mentioned. In these methods, drugs are dispersed in a matrix structure. Further, when a matrix structure is formed on the surface of the insert, its thickness is preferably 5.0 fm to 0.1 mm so as not to impair the flexibility of the insertion part and the medicine holding part. However, when the substance that forms the matrix structure is as flexible as or more than the drug holding part, such as gel or gel, the maximum may be 1.0 mm.

The material constituting the matrix structure is preferably a biostable polymer or a bioabsorbable polymer. Here, the matrix structure refers to a structure in which the polymer is intertwined in a complicated manner such as by crosslinking, and includes a matrix structure used for a known sustained-release system for drugs.

The bioabsorbable polymer is not particularly limited as long as at least a part of the polymer can be absorbed by the living body. For example, polycaprolactone, poly (lactide-co-glycolide), poly (hydroxybutyrate), poly ( Hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, polyglycolic acid, poly (D, L) lactic acid, poly (glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphospho Ester urethane, polyamino acid, cyanoacrylate, poly (trimethylene carbonate), poly (iminocarbonate), copoly (ether-ester), polyalkylene oxalate, polyphosphazene; fibrin, fibrinogen, cellulose, cellulose Loin, starch, collagen, and hyaluronic acid. The biostable polymer is not particularly limited as long as it is a polymer that is stable to the living body, and examples thereof include polyurethane, silicone, and polyester. As other polymers, polyolefins, copolymers of polyisobutylene and ethylene-alpha olefins, copolymers of acrylic acid polymers, copolymers of vinyl halide polymers such as polyvinyl chloride; polyvinyl methyl ether Such as polyvinyl ether; polyvinylidene fluoride, polyvinylidene halide such as polyvinylidene chloride; polyacrylonitrile, polyvinyl ketone; polyvinyl aromatic such as polystyrene, polyvinyl ester such as polyvinyl acetate; ethylene-methyl methacrylate copolymer, etc. Copolymer of vinyl monomers or olefin, copolymer of acrylonitrile and styrene, ABS resin, copolymer of ethylene and vinyl acetate; nylon 6, Polyamides such as polycaprolactam; Alkyd resins; Polycarbonates; Polyoxymethylenes; Polyimides; Polyethers; Epoxy resins; Polyurethanes; Rayon; Rayon triacetates; Nitrate; cellulose propionate; cellulose ether; carboxymethyl cellulose; chitin, chitosan and the like can also be used for the matrix structure. These may be used alone or in combination of two or more.

Drugs held in the drug holding unit 101 are not limited to the following, but include, for example, pharmaceuticals, quasi drugs; dietary supplements such as various nucleic acids, various vitamins, and iron preparations. Among these, from the viewpoint of ease of holding the drug holding unit 101, liquid drugs are preferable. Here, the medicines widely include things that are intended to affect the structure or function of the human body.

The contact surface 102 is a portion where the drug holding portion 101 is exposed between the proximal end 103 and the distal end 104 of the insert 10A. In the present embodiment, the contact surface 102 is formed on the entire surface of the insert 10A. Has been. At least a part of the contact surface 102 comes into contact with the mucous membrane of the nasal cavity b during placement. The insertion body 10A is held at the proximal end 103 by the nasal cavity mounting body 20A at the time of indwelling, but the distal end 104 becomes a free end, so that the insertion body 10A is deformed according to gravity and the shape of the insertion body 10A. The surface on the proximal end 103 side of this is in contact with the adjacent mucosa. If the medicine holding part 101 is exposed as the contact surface 102 on the surface of the insert 10A, the contact surface 102 comes into contact with the adjacent mucosa.

The proximal end 103 and the distal end 104 are both ends in the longitudinal direction of the insert 10A. When the nasal cavity placement device 1A is placed, the proximal end 103 is disposed on the nostril (FIG. 3 (A) h) side. The distal end 104 is arranged on the pharynx (FIG. 3 (A) i) side. The insert 10A is a tube having a circular cross section, and has a proximal end opening 105 on the proximal end 103 side and a distal end opening 106 on the distal end 104 side.

Here, the section being circular may be circular or substantially circular in cross section. If the cross section is circular or substantially circular, there is a tendency that the insert can be more smoothly inserted into the nasal cavity due to the small friction generated when the insert is inserted into the nasal cavity.

(Configuration-nasal cavity body)
The nasal cavity mounting body 20A is provided in the nasal cavity placement device 1A in order to mount the insert 10A on the nasal cavity b. The nasal cavity mounting body 20 </ b> A includes a spring-like member 201 having a C-shaped cross section and a support body 202. Since the spring-like member 201 is locked at the position of the nasal vestibule when the insertion body 10A is indwelled, the spring-like member 201 is locked without applying a load to the site outside the nasal cavity b.

FIG. 2 is a diagram schematically illustrating an example of a state in which the spring member 201 according to the first embodiment is used for the nose. The spring-like member 201 is an elastic body having a C-shaped cross section. The spring member 201 locks the insert 10A in the nasal cavity by pressing the nasal wing k and the nasal column j from the inside. The spring-like member 201 is made of spring steel, for example.

The support portion 202 extends in the longitudinal direction toward the insert 10A and is connected to the proximal end 103 of the insert 10A. This support portion 202 has higher rigidity than the insert 10A.

The material of the support portion 202 can be selected as appropriate as long as it has higher rigidity than the insert 10A. An example is polypropylene. Although there is no particular limitation on the method of connecting to the insert 10A, for example, a method of intubating the support 202 into the insert 10A, a method of adhering or joining each end of the support 202 and the insert 10A, a support A method of integrally forming 202 and the insert 10 </ b> A may be mentioned.

The shape of the support portion 202 is not particularly limited, but is preferably a shape that increases rigidity, for example, a solid bar shape. The support portion 202 has a length of, for example, 1.0 mm to 15 mm. However, when the mass of the insert 10A is 5000 mg or more, it is desirable that the length of the support 202 is 15 mm or more in order to prevent the insert 10A and the support 202 from peeling off and dropping off. Further, when the cross section is substantially circular, the outer diameter is, for example, 8.0 mm to 20 mm. Note that when the support portion 202 is intubated and used in the insertion body 10A, the length is increased by the amount of intubation.
(how to use)

Next, a method of using the nasal cavity placement device 1A will be described with reference to FIG. Here, FIG. 3 (A) is a front view seen through the nose from the nasal septum side, schematically showing an example of a state in which the insert 10A according to Embodiment 1 is placed in the nasal cavity b. FIG. 3B is a perspective view of the nose from the nasal column side. FIG. 3C is a rear view seen through the nose from the left cheek side.

3 (A) to 3 (C), each part of the nose includes the paranasal sinus a, the nasal cavity b, the kieselbach c, the middle turbinate d, the lower nasal turbinate e, the lower nasal passage f, the upper lip g, the nostril h, and the pharynx. i, nasal column j, nose wing k, and nose tip l are shown.

First, the distal end 104 side of the insert 10A is picked up and applied to the nostril h. Next, while preventing the insertion body 10A from being removed from the nostril h, the nasal cavity mounting body 20A is picked up and the insertion body 10A is inserted into the nasal cavity b. When the distal end 104 of the insertion body 10A is inserted from the nostril h into the nasal cavity b, the insertion is performed while grasping the nasal cavity mounting body 20A of the nasal cavity placement device 1A. Then, an external force acts on the insertion body 10A through the proximal end 103 to which the support portion 202 of the nasal cavity mounting body 20A is connected, and the insertion body 10A is inserted into the nasal cavity b. At this time, since the support portion 202 is larger in rigidity than the insertion body 10A, the support portion 202 is not bent at the time of insertion, and an external force can be efficiently transmitted to the insertion body 10A.

When inserting the insertion body 10A into the nasal cavity b, the spring-like member 201 is inserted from the nostril h while the spring-like member 201 is closed by the external force of the fingers. If it does so, fingers will remove | deviate from the spring-shaped member 201 naturally, and the spring-shaped member 201 will be open | released from an external force and will become an open shape. The opened spring-like member 201 opens and stops in the nasal vestibule or nostril h, and locks the insert 10A. Thereafter, when the nasal cavity indwelling device 1A is pulled out after being left for a predetermined time, the spring-like member 201 can be directly grasped and pulled out.

Thereby, as shown in FIGS. 3A to 3C, the insertion body 10A is inserted into the nasal cavity b from the nostril h and placed in the nasal cavity b. The nasal cavity placement device 1A does not reach the pharynx i.

In the present embodiment, the contact surface 102 is in contact with the mucous membrane of the kieselbach site c. The Kieselbach region c has a concentration of veins under the mucous membrane of the region, and therefore, the absorption rate of the drugs tends to be higher than that of the mucous membrane of the nasal cavity b. As preferred.

As shown in FIGS. 3A to 3C, since the insert 10A is an annular tube, even when the insert 10A is placed in the nasal cavity, the proximal end opening 105, the distal end opening 106, In between, fluids such as air and mucus flow into and out of the insertion body 10A, and physiological actions such as nasal breathing are unlikely to be hindered.

As shown in FIGS. 3A to 3C, the proximal end opening 105 is disposed in the kieselbach part c, and fluid such as air and mucous membrane flows from the opening 105 into the insert 10A. In the case of air, since the mucous membrane is exposed between the nostril and the opening 105, the inspiration from the nostril h to the pharynx i comes into contact with the exposed mucous membrane and is heated and humidified.

Also, since the mucous membrane and the drug holding part can be brought into contact with each other for a long time, a specific effect is exhibited when a specific drug is used. For example, when a water-soluble drug having low gastrointestinal absorbability is used as a drug, even if it is low absorbable, absorption can be maintained for a long period of time, so that a sufficient therapeutic effect can be desired. In addition, the absorption rate is fast and metabolized quickly in the body, but if it is harmful to the human body at high concentrations, once the nasal indwelling device of this embodiment is used, the drugs are gradually released in small amounts, Its medicinal properties can be maintained safely.

[Modification to Embodiment 1]
Although the first embodiment has been described above, the specific configuration and means of the first embodiment can be arbitrarily modified and improved within the scope of the technical idea of each invention described in the claims. it can. Hereinafter, such a modification will be described.

(About the insert)
FIG. 4A is a front view schematically showing a modification of the insert according to the first embodiment. FIG. 4B is a left side view. FIG. 5 (A) is a front view seen through the nose from the nasal septum side, schematically showing a modification of the state in which the insert according to Embodiment 1 is placed in the nasal cavity. FIG. 5B is a perspective view of the nose from the nasal column side. FIG. 5C is a rear view of the nose seen through from the left cheek side.

In Embodiment 1 described above, the insert having a tube with an annular cross section has been described. However, the present invention is not limited to this, and for example, as shown in FIG. 4B, the insert 10B having a U-shaped cross section. It may be. The U-shape does not need to be strictly U-shaped, and includes, for example, V-shape and C-shape.

Since the insert 10B is a tube having a U-shaped cross section, when the insert 10B is placed in the nasal cavity, an opening is formed in the insert 10B along the longitudinal direction. Since there is an opening, the physiological action of humidification and warming of inhalation by the mucous membrane during placement is more difficult to be inhibited. Moreover, since the back surface of the tube of the insertion body 10B can be easily exposed by opening the opening, it is easy to apply drugs to the back surface.

As shown in FIG. 4A, the spring-like member 201a is disposed at a predetermined angle with respect to the insert 10B. Thereby, it can be adapted to the shape of the nasal cavity, and the uncomfortable feeling at the time of placement can be alleviated.

Further, as shown in FIG. 4A, the support 202a is intubated into the insert 10B. As a result, the rigidity of the insertion body 10B is increased, and bending of the insertion body 10B during insertion into the nasal cavity can be suppressed.

Also, for example, the cross-sectional shape of the insert is not limited to the described annular and U-shape. The shape obtained by deforming the annular shape may be, for example, a triangle, a quadrangle, a pentagonal polygon; a shape having a concave shape or a convex shape.

For example, the insert is not particularly limited as long as it is a tube, and may be a tube having a slit in the longitudinal direction. As a method of forming a slit in the tube, for example, a method of cutting out a part of the tube after manufacturing the tube, forming the sheet by winding the sheet, without bonding the ends of the sheet to each other in the wound direction There is a method in which a slit is provided between them.

Further, for example, in the above embodiment, the length of the insert does not reach the pharynx i in order to reduce the uncomfortable feeling at the time of placement. If there is, the length of the insert may reach the pharynx i.

In addition, for example, a method for enabling the drug holding unit 101 to hold the drug is not particularly limited. For example, a method of applying drugs to the surface of the tube by spraying, a method of forming the tube as a porous body, a method of holding the drug of fluid in the tube, a tube made of a material having a certain permeability, and a tube And a method of including the drug inside the tube and a method of forming the tube itself from the material of the drug. In the method of applying a drug to the surface of the tube, a larger amount of the drug can be held by holding the drug not only on the surface of the tube but also on the back and inside.

In the first embodiment, the example in which the drugs are absorbed only from the contact surface 102 through the mucous membrane of the nasal cavity b has been described. However, the present invention is not limited to this. For example, at least a part of the drug from the contact surface 102 is gradually discharged from the drug holding part 101 due to warming at body temperature or mucus secreted from the mucous membrane, and flows to the pharynx i to be administered to the digestive tract. May be.

In the first embodiment, the example in which all of the medicine holding unit 101 is exposed as the contact surface 102 of the insert 10A on the entire surface of the insert 10A has been described, but is not limited thereto. For example, a part of the medicine holding unit 101 may be exposed as a contact surface 102 on a part of the insertion body 10A. For example, the medicine holding part 101 is included in the insertion body 10 </ b> A, and a part of the medicine holding part 101 is exposed as the contact surface 102. Since the entire medicine holding unit 101 is not exposed, the speed at which the medicine is absorbed by the mucous membrane can be reduced.

[Embodiment 2]
Next, a second embodiment will be described. In this embodiment, the insert includes a thin plate portion, and the shape of the insert is different from that of the first embodiment. In addition, about the structure substantially the same as the structure of Embodiment 1, the code | symbol and / or name which are the same as what was used in this Embodiment 1 are attached | subjected as needed, and the description is abbreviate | omitted.

(Constitution)
First, the configuration of the nasal cavity placement device 2A will be described with reference to FIGS. Here, FIG. 6A is a front view schematically showing an example of the nasal cavity indwelling device according to the second embodiment. FIG. 6B is a left side view thereof. FIG. 7A is a front view seen through the nose from the nasal septum side, schematically showing an example of a state in which the insert according to Embodiment 2 is placed in the nasal cavity. FIG. 7B is a view seen through the nose from the nasal column side. FIG. 7C is a rear view seen through the nose from the left cheek side.

(Configuration-Insert)
As shown in FIG. 6A, the nasal cavity indwelling device 2A includes an insert 11A and a nasal cavity mounting body 20B. The insert 11A includes a thin plate-like portion 110 provided with a medicine holding portion 101, and a proximal end 103 and a distal end 104 in the longitudinal direction. As shown in FIG. 6A, the thin plate-like portion is longer in the short direction than the nasal cavity mounting body 20B. Therefore, in a state where the insert 11A is placed in the nasal cavity (see FIGS. 7A to 7C), the thin plate-like portion 110 of the insert 11A extends widely in the nasal cavity b and is provided in the thin plate-like portion 110. The medicinal product holding part 101 can be brought into contact with the mucous membrane in the nasal cavity b in a larger area.

The thin plate portion 110 is a material that can be elastically deformed. Here, the term “elastically deformable” means that the insert 11A is elastic enough to allow the required deformation while it is inserted from the nostril h to the nasal cavity b. The elastically deformable material is, for example, one in which the thin plate portion 110 is formed of a material such as rubber containing silicone. Since the thin plate-like portion 110 can be elastically deformed, when the insert 11A is inserted into the nasal cavity b, it is inserted while being elastically deformed in accordance with the shape of the nasal cavity b, so that the insertion is easy.

The width of the thin plate-like portion 110 gradually increases from the proximal end 103 along the approximate center in the longitudinal direction of the insert 11A, and gradually decreases along the distal end 104 from the approximately longitudinal center. When the insertion body 11A is inserted from the nostril h, the insertion is easy because the insertion is performed from the narrow distal end 104.

The maximum width of the thin plate-like portion 110 is not particularly limited as long as the surface can contact the mucous membrane when placed in the nasal cavity. The length is preferably from 10 mm to 80 mm, more preferably from 10 mm to 40 mm, and even more preferably from 10 mm to 20 mm from the viewpoint of reducing the uncomfortable feeling during placement. The width of the thin plate portion 110 on the proximal end 103 side is preferably 8.0 mm to 30 mm. The width of the thin plate portion 110 on the distal end 104 side is preferably 2.0 mm to 8.0 mm. The thickness is preferably 0.1 mm to 5.0 mm.

(Configuration-nasal cavity body)
The nasal cavity mounting body 20B includes a spring-like member 201a and a support portion 202a. The support portion 202a is connected to the proximal end 103 of the insert 11A and is inserted into the insert 11A. The support portion 202a has higher rigidity than the insertion body 11A. Since the insertion body 11A including the thin plate-like portion 110 tends to have a large deformation amount when inserted, the support portion 202a is intubated into the insertion body 11A.

[Modification of Embodiment 2]
Although the second embodiment has been described above, the specific configuration and means of the second embodiment can be arbitrarily modified and improved within the scope of the technical idea of each invention described in the claims. it can. Hereinafter, such a modification will be described.

(About the insert)
FIG. 8A is a front view schematically showing Modification Example 1 of the insert according to Embodiment 2. FIG. FIG. 8B is a left side view. In the second embodiment, the example in which the insert body is provided with a thin plate-like portion having a plate-like shape has been described. However, the present invention is not limited to this, and a configuration like the insert body 11B shown in FIG. May be. That is, the thin plate-like portion 110 may be configured by connecting the two sheet-like members 110a to each other in the thickness direction and connecting them with the connecting portion 110b. It should be noted that the number of sheet-like members to be connected is not limited to two and may be larger.

In the insertion body 11B, since each of the sheet-like members 110a is in contact with the mucous membrane, the medicine holding part 101 can be brought into contact with the mucous membrane at more places. Moreover, since the surface area of the whole thin plate-shaped part 110 increases, the area of the chemical | medical agent holding | maintenance part 101 which contacts a mucous membrane can be enlarged. Further, fluid such as air can come and go through the gap between the sheet-like member 110a and the connecting portion 110b. The sheet-like member 110a has the same shape and size as the thin plate-like portion 110 of the insert 11A. However, the thickness of the sheet-like member 110a is preferably 0.1 mm to 5.0 mm in the whole connected thin plate-like portions.

FIG. 9 (A) is a front view schematically showing Modification Example 2 of the insert according to Embodiment 2. FIG. FIG. 9B is a left side view. In Embodiment 2 described above, an example in which a thin plate-like portion having a uniform thickness is provided has been described. However, the present invention is not limited to this, and an insert can hold a drug like an insert 11C illustrated in FIG. You may provide the thin plate-shaped part which has a cross section which is a shape which becomes thin toward the surface 102 side which the part 101 exposes.

When the insert 11C is inserted from the nostril h toward the nasal cavity b, the cross section of the thin plate-like portion 110 has a triangular shape similar to the shape of the nostril h and the nasal cavity b, and is required for the insert 11C. Deformation is small. Therefore, the insert 11C can be easily inserted into the nasal cavity. Moreover, since there exists a part (thick) where the width | variety of a thin-plate shaped part is large, a chemical | medical agent can be hold | maintained abundantly in the part.

[Modifications to Embodiments 1 and 2]
While the first and second embodiments have been described above, the specific configurations and means of the first and second embodiments are arbitrarily modified and modified within the scope of the technical idea of each invention described in the claims. It can be improved. Hereinafter, such a modification will be described.

(About the insert)
In Embodiment 1 described above, the structure (the porous structure, the matrix structure, etc.) in which the drug holding unit holds the drug in the layer of the insert has been described. However, the method for holding the drug is limited to this. Absent. The medicine holding unit may hold the medicine on the surface of the insert. In this case, since it is not necessary to provide the porous structure or matrix structure as described above in the insertion body, the structure of the medicine holding part can be simplified.

For example, the liquid medicine is directly applied to the surface of the insert, and the medicine is held on the surface of the insert by the surface tension acting on the interface between the liquid medicine and the surface of the insert. Good. More specifically, the liquid medicine is directly applied to the outer surface of the insert, or the insert is made of a material that can penetrate the medicine from the inner surface toward the outer surface. In some cases, a method of directly applying a liquid drug to the inner surface of the insert may be mentioned.

In this case, it is possible to provide a medicine holding part by directly applying the medicine to a desired position even after the insertion body is manufactured, and the degree of freedom of the place where the medicine holding part is installed is greatly improved.

The liquid drug is not particularly limited, but a drug containing a thickener or a gelling agent is preferable from the viewpoint of obtaining higher surface tension. Here, the “thickening agent” means a raw material in which a liquid drug is viscous by being contained in the drug. The “gelling agent” means a raw material that can be solidified or semi-solidified by being contained in the drug. The drugs may contain a thickener and a gelling agent in combination, or each may be contained alone. Specific examples of the thickener include cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose and carboxymethylcellulose; modified starch, xanthan gum, guar gum and tamarind gum. Specific examples of the gelling agent include agar and carrageenan.

In addition to the above-described components of the drug, the liquid drug may further contain a solvent and a dispersant from the viewpoint of adjusting the viscosity of the drug and improving the dispersibility of the drug. The solvent is not particularly limited as long as it dissolves an active ingredient in pharmaceuticals. For example, water, monohydric alcohols such as ethanol, diols such as propylene glycol (dihydric alcohols), triols such as glycerin (3 (Hydric alcohol). In addition, the dispersant is not particularly limited as long as it disperses the active ingredient in the drug. For example, water, a monohydric alcohol such as ethanol, a diol (dihydric alcohol) such as propylene glycol, glycerin, and the like. Examples include triol (trihydric alcohol) and water-soluble polymer. The solvent or dispersant contained in the drug can be removed from the drug by means such as heating or vacuum drying after the drug is held on the surface of the insert. For this reason, by further containing a solvent or a dispersant in the drug, liquid components such as the solvent and the dispersant can be removed on the surface of the insert, and the drug in a thinned state can be obtained. Further, the thinned drugs are compared with the case where the drugs are inserted and the liquid drugs are held on the surface of the insert as it is due to the adhesive force acting on the interface between the drugs and the surface of the insert. Thus, the drugs can be held on the surface of the insert more stably.

In addition to the direct application described above, for example, the drug holding unit holds the drug on the surface of the insert. For example, a thinned drug (film preparation) may be stacked on the insert. Conceivable. For example, a liquid drug is preliminarily removed from the insert itself or an intermediate medium other than the insert by heating or vacuum drying to form a film preparation, which is then inserted via an adhesive or adhesive. A method of holding the drugs by laminating the film preparation on the surface of the body is mentioned. The size and thickness of the film preparation are not particularly limited as long as they are appropriately set according to the amount and quality of the active ingredient of the drug and the additive contained and can be held in the insert. The adhesive and the pressure-sensitive adhesive are not particularly limited as long as they are not invasive to the human body and the film preparation can be held in the insert, and known materials can be used. By providing a film preparation on the surface of the insert, a desired position of the insert can be used as a medicine holding part, and the medicine can be easily administered to a desired position in the nasal cavity.

The adhesive is not particularly limited as long as it can bond the objects, but for example, a solution containing cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, etc .; wheat And paste made from starch derived from tapioca. Moreover, as an adhesive, you may use what can peel off the target stuck together later. By using such an adhesive, the film preparation can be held once on the surface of the insert, and then the film preparation can be held again at a position on a different surface of the insert. It becomes easier to administer the drugs to a desired position.

Furthermore, in order to apply the liquid medicine or film preparation on the surface of the insert, the liquid medicine holding part holds the medicine on the surface of the insert. It may be achieved by spraying on the surface. Further, in order to more strongly hold the drugs on the surface of the insert, the above-described adhesive or pressure-sensitive adhesive may be provided in advance on the surface of the insert, and the spray agent may be sprayed on the surface. By providing the drugs on the surface of the insert by spraying the spray, the drugs can be easily held.

Also, the drugs may be those in which the above-mentioned pressure-sensitive adhesive or adhesive contains a drug component. By applying such drugs to the surface of the insert as the above liquid drugs or film preparations, the drugs can be held with better adhesion on the surface of the insert.

Further, for example, as the drug holding unit, a configuration in which a plurality of different types of drugs are stacked may be used, or a structure in which the drugs have a concentration gradient in the thickness direction may be used. For example, by providing the surface of the insert, the adhesive, the first film preparation, the adhesive, and the second film preparation in this order, the first film preparation contains a high concentration of the active ingredient, and the second film preparation contains the low active ingredient. A concentration gradient of drugs may be provided in the thickness direction of the insert, which is included in the concentration. Moreover, it can design so that the 1st film formulation contains a fat-soluble active ingredient and the 2nd film formulation contains the water-soluble active ingredient, and administers the medicine of a different composition one by one.

In the configuration in which the drug holding unit holds the drug on the surface of the insert, the drug holding unit increases the affinity with the liquid drug or film preparation held in the drug holding unit. Surface treatment may be applied to the outer surface or inner surface of the insert so as to facilitate the process.

Examples of the surface treatment include a treatment in which the insert is immersed in an aqueous solution of a known acid or base, a treatment in which the insert is left in an ozone atmosphere, and a treatment in which a silane coupling agent and a polymer are reacted with the material on the insert surface. For example, the surface of the insert made of silicone is high in affinity with water-soluble drugs and low in affinity with fat-soluble drugs because the silicone end has a hydroxyl group. . Therefore, the surface of the insert becomes fat-soluble by reacting the insert made of silicone with the silane coupling agent and a polymer reactive with the silane coupling agent on the surface of the insert. The affinity with fat-soluble drugs can be increased, and the fat-soluble drugs can be more strongly retained.

In Embodiments 1 and 2 described above, the nasal cavity indwelling device including one insert has been described. However, the present invention is not limited to this, and a nasal cavity indwelling device including two inserts may be used. Two inserts are respectively inserted into the two nostrils. There is no particular limitation on the size of both the length, thickness, etc. For example, one insert may have the same length as the above-described insert, and the other insert may be relatively short. Both may have the same size. In addition, each of the two inserts may be provided with a medicine holding part, or only one of them may be provided. Further, for example, one of the inserts may include a drug holding unit that holds a fat-soluble drug, and the other insert may include a drug holding unit that holds a water-soluble drug. In this case, different types of drugs can be held simultaneously.

(About nasal cavity wearing body)
FIG. 10 is a front view schematically showing an example of a state in which the locking part of the nasal cavity mounting body according to the embodiment is locked to the nasal vestibule. FIG. 11 is a front view schematically showing a modification of the nasal cavity wearing body according to the embodiment. FIG. 12 is a front view schematically showing a modification of the nasal cavity mounting body according to the embodiment of the present invention. In the first and second embodiments, an example of a nasal cavity mounting body that is a spring member having a C-shaped cross section has been described. However, the present invention is not limited to this, and has a circular outer periphery as shown in FIGS. A nasal cavity mounting body that includes the locking

portions

203a, 203b, and 203c and that is locked to the nasal vestibule when the insertion body is placed may be used.

As shown in FIG. 10, the nasal cavity mounting body 20C includes a locking portion 203a that is a portion having the largest outer diameter, and a spring 204 that is elastically deformed in the insertion direction. The nasal cavity mounting body 20C is connected to the insertion body 10A. The nasal cavity mounting body 20C preferably has a substantially cylindrical shape that is hollow toward the X direction. This allows the fluid to flow into and out of the pharynx from the nostril h together with the insertion body 10A. The nasal cavity mounting body 20C is provided with a locking portion 203a on the end side connected to the insertion body 10A, and the outer diameter decreases toward the other end side not connected to the insertion body 10A. The spring 204 has an effect of reducing external force in the insertion direction, and can be adjusted so that the nasal cavity mounting body 20C is not inserted too much.

As shown in FIG. 11, the nasal cavity mounting body 20D is configured in the same manner as the nasal cavity mounting body 20C shown in FIG. 10 except that it includes a plurality of protrusion-like locking portions 203b. Since the locking force on the nasal vestibule is increased by the plurality of locking portions 203b, the nasal cavity placement device can be more stably attached.

As shown in FIG. 12, the nasal cavity mounting body 20E is connected to the insertion body 10A and has a cone part 205 having a plurality of openings 205a, and is connected to the cone part 205 to constitute the end of the nasal cavity mounting body 20E. Engaging portion 203c. The cross-sectional diameter of the cone portion 205 gradually increases from the connecting end of the insert 10A toward the locking portion 203c, and is connected to the locking portion 203c having the maximum cross-sectional diameter. With this shape, the nasal cavity mounting body 20E can be easily picked with a finger or the like, so that the nasal cavity indwelling device can be more easily attached and detached. The opening 205a communicates with the inside of the tube of the insert 10A, and allows fluid to flow into and out of the pharynx from the nostril h.

Further, for example, the nasal cavity mounting body may be configured to include a pair of sandwiching portions 206 facing each other and an elastically deformable 207 connecting the pair of sandwiching portions 206 as shown in FIG. In the nasal cavity mounting body 20F, the one connected to the insertion body 10A of the pair of holding portions 206 is inserted from one nostril h, and the other holding portion 206 is inserted into the other nostril h. Since any of the clamping portions 206 are connected to the connecting portion 207, all of them are not inserted into the nostril h. In this case, the pair of holding portions 206 are connected by the connecting portion 207 with the nose column j interposed therebetween. As a result, the nasal cavity indwelling device does not go too far into the nasal cavity b and cannot be pulled out. Alternatively, the other holding part 206 may be arranged outside the nose wing k, and the pair of holding parts 206 may be connected by the connecting part 207 with the nose wing k interposed therebetween.

1A, 1B, 2A, 2B, 2C ... nasal

cavity placement devices

10A, 10B, 11A, 11B, 11C ... Insert 110 ... Thin plate portion 110a ... Sheet-like member 110b ... Connection portion 101 ... Drug holding portion 102 ... Contact surface 103 ... Proximal end 104 ... Distal end 105 ... Proximal end opening 106 ...

Distal end opening

20A, 20B, 20C, 20D, 20E, 20F ... Nasal

cavity mounting body

201, 201a ... Spring-

like member

202, 202a ...

Support part

203a , 203b, 203c ... locking part 204 ... spring 205 ... cone part 205a ... opening 206 ... clamping part 207 ... connecting part a ... sinuses, b ... nasal cavity, c ... kieselbach region, d ... middle turbinate, e ... bottom Nasal concha, f ... lower nasal passage, g ... upper lip, h ... nostril, i ... pharynx, j ... nasal column, k ... nasal wing, l ... nasal tip

Claims

A nasal indwelling device comprising an insert having a longitudinally proximal end and a distal end, for placing the insert in the nasal cavity,
The insert includes a drug holding unit capable of holding drugs,
At least a part of the medicine holding part is exposed on the surface between the proximal end and the distal end of the insert, and is configured such that the surface and the nasal mucosa come into contact when placed. Nasal placement device.
A nasal cavity mounting body for mounting the insert body on the nasal cavity;
The nasal cavity placement device according to claim 1, wherein the nasal cavity mounting body is connected to a proximal end of the insert.
The nasal cavity placement device according to claim 2, wherein the insert is a tube having an annular cross section.
The nasal cavity placement device according to claim 3, wherein an opening is defined between the nasal cavity wearing body and a proximal end of the insertion body.
The nasal cavity mounting body includes a support portion that extends toward the insertion body and connects to the proximal end of the insertion body,
The nasal cavity indwelling device according to claim 4, wherein the support portion has higher rigidity than the insertion body.
The nasal cavity placement device according to claim 1 or 2, wherein the insert is a tube having a U-shaped cross section.
The insert includes a thin plate-like part provided with the medicine holding part,
The nasal cavity indwelling device according to claim 2, wherein the thin plate-like portion is longer in the short direction than the nasal cavity wearing body.
The nasal cavity placement device according to claim 7, wherein the thin plate portion is elastically deformable.
The nasal cavity placement device according to claim 7 or 8, wherein the thin plate-like portion is configured by connecting a plurality of sheet-like members to each other.
The nasal cavity indwelling device according to any one of claims 7 to 9, wherein a cross section of the thin plate-like portion has a shape that becomes thinner toward the surface side where the medicine holding portion is exposed.
The nasal cavity placement device according to any one of claims 7 to 10, wherein a length of the thin plate portion in a short direction is reduced along the distal end.
The nasal cavity mounting body includes a support portion that is connected to the proximal end of the insert and is intubated by the insert.
The nasal cavity indwelling device according to any one of claims 7 to 11, wherein the support portion has higher rigidity than the insert.
The nasal cavity placement device according to any one of claims 2 to 12, wherein the nasal cavity wearing body includes a pair of holding parts facing each other and an elastically deformable connecting part that connects the pair of holding parts.
The nasal cavity wearing body includes a locking portion having a circular outer periphery,
The nasal cavity placement device according to any one of claims 2 to 12, wherein the locking portion is locked to the nasal vestibule when the insert is placed.
The nasal cavity placement device according to any one of claims 2 to 12, wherein the nasal cavity wearing body is a spring-like member having a C-shaped cross section.
The nasal cavity placement device according to any one of claims 1 to 15, wherein the nasal mucosa includes at least a kieselbach region.
The nasal cavity indwelling device according to any one of claims 1 to 16, wherein the medicine holding part has a porous structure.
The nasal cavity indwelling device according to any one of claims 1 to 17, wherein the medicine holding unit has a matrix structure.